Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia

American Journal of Hematology

Volumn 88, Issue 2, 2013, Pages 97-101

  Bregman, David B ^a,b   Morris, David ^c   Koch, Todd A ^a   He, Andy ^a   Goodnough, Lawrence T ^d  

^a Luitpold Pharmaceuticals Inc   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; HEPCIDIN;

ARTICLE; HEMOGLOBIN BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON THERAPY; PATIENT COMPLIANCE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

ADULT; ANEMIA, IRON-DEFICIENCY; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; DIETARY SUPPLEMENTS; FEMALE; FERRIC COMPOUNDS; FERRITINS; FERROUS COMPOUNDS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON, DIETARY; MALE; MALTOSE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TRANSFERRIN;

EID: 84872951347     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23354     Document Type: Article

References (21)

1. Clark SF. Iron deficiency anemia. Nutr Clin Pract 2008;23:128-141.
2. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
3. Coyne DW. Hepcidin: Clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011;80:240-244.
4. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
5. Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 2006;290:G199-G203.
6. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011;2011:538-542.
7. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116:4754-4761.
8. Freireich EJ, Miller A, Emerson CP, et al. The effect of inflammation on the utilization of erythrocyte and transferrin bound radioiron for red cell production. Blood 1957;12:972-983.
9. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347-360.
10. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis. Transfusion 2012;52:1584-1592.
11. Szczech LA, Bregman DB, Harrington RA, et al. Comparison of high dose carboxymaltose to oral or IV iron in subjects with iron deficiency anemia not suitable for oral iron. Am Soc Nephrol 2011;22:405A.
12. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-1192.
13. Seid MH, Derman RJ, Baker JB, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial. Am J Obstet Gynecol 2008;199:435 e431-e437.
14. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion 2009;49:2719-2728.
15. Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: A randomized controlled trial. Obstet Gynecol 2007;110:267-278.
16. Zaritsky J, Young B, Wang HJ, et al. Hepcidin-A potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-1056.
17. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012;366:348-359.
18. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009;122:78-86.
19. Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976-981.
20. Mast AE, Blinder MA, Gronowski AM, et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998;44:45-51.
21. Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011;26:1599-1607.